Key Points
- Insider trade: Dr. Martens insider Ije Nwokori bought 233 shares on May 13 at GBX 64 each, totaling £149.12. This follows a recent sale of 204,051 shares in mid-April and a smaller buy the day before that.
- Stock snapshot: Dr. Martens shares opened at GBX 64.40, near their 50-day average of GBX 64.06 and below the 200-day average of GBX 71.91. The company has a market cap of about £622.87 million.
- Analyst view: Analysts currently rate Dr. Martens as a Moderate Buy, with two Buy ratings and two Hold ratings. Berenberg Bank reiterated a Buy rating and set a GBX 114 price target.
Dr. Martens plc (LON:DOCS - Get Free Report) insider Ije Nwokori bought 233 shares of Dr. Martens stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of GBX 64 per share, with a total value of £149.12.
Ije Nwokori also recently made the following trade(s):
- On Wednesday, April 15th, Ije Nwokori sold 204,051 shares of Dr. Martens stock. The stock was sold at an average price of GBX 66, for a total transaction of £134,673.66.
- On Tuesday, April 14th, Ije Nwokori bought 232 shares of Dr. Martens stock. The stock was bought at an average cost of GBX 65 per share, with a total value of £150.80.
Dr. Martens Price Performance
Shares of LON DOCS opened at GBX 64.40 on Friday. The firm has a market cap of £622.87 million, a PE ratio of 37.88, a PEG ratio of 6.40 and a beta of 0.24. The company has a current ratio of 2.18, a quick ratio of 1.13 and a debt-to-equity ratio of 120.66. Dr. Martens plc has a 1-year low of GBX 53.05 and a 1-year high of GBX 100.87. The company has a fifty day moving average price of GBX 64.06 and a 200 day moving average price of GBX 71.91.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently commented on the stock. Berenberg Bank restated a "buy" rating and set a GBX 114 price objective on shares of Dr. Martens in a research note on Wednesday, May 6th. Royal Bank Of Canada restated a "sector perform" rating on shares of Dr. Martens in a research note on Tuesday, February 3rd. Two investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, Dr. Martens presently has an average rating of "Moderate Buy" and a consensus price target of GBX 3,057.
Check Out Our Latest Analysis on DOCS
Dr. Martens Company Profile
(
Get Free Report)
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
